Trial Profile
A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 06 Jun 2023 Interim results (n=33) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 10 Dec 2022 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 10 Dec 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.